Antibiotic Treatment for Chronic Rhinosinusitis

Introduction to Antibiotic Use

The American Academy of Otolaryngology makes a strong recommendation against the use of antibiotics if there is no significant or persistent purulent nasal discharge visible on examination, emphasizing the need for a thorough physical examination before considering antibiotic treatment 1

Diagnosis of chronic rhinosinusitis should be confirmed, with symptoms lasting more than 12 weeks, to differentiate it from acute exacerbations 1
The presence of purulent drainage on physical examination should be confirmed before considering antibiotics, as this is a key indicator of potential bacterial infection 1
Optimization of anti-inflammatory treatment, including intranasal corticosteroids and saline nasal irrigations, should be prioritized before considering antibiotics, as these are the foundation of treatment for chronic rhinosinusitis 1

The use of short-course antibiotics (2-4 weeks) in chronic rhinosinusitis has limited evidence, with amoxicillin/clavulanate for 2 weeks showing no benefit in patients with acute exacerbation of chronic rhinosinusitis compared to placebo, highlighting the need for more targeted antibiotic use 2
The European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) 2020 concluded that it is uncertain whether the use of short-course antibiotics has an impact on outcomes in adult patients with chronic rhinosinusitis compared to placebo, due to the very low quality of evidence 3

Roxithromycin 150 mg daily for 12 weeks demonstrated significant improvements in symptom scores and nasal endoscopy in patients without nasal polyps, particularly those with low IgE levels (<200 μg/L), suggesting a potential role for macrolides in specific patient populations 1
Azithromycin 500 mg weekly for 11-12 weeks showed contradictory results, with 50% of patients reporting improvement 12 weeks after completing treatment versus 9% with placebo, highlighting the need for further research into the efficacy of macrolides in chronic rhinosinusitis 1

Doxycycline 200 mg on day 1, then 100 mg/day for 20 days, significantly reduced postnasal drip at week 2 (p=0.044) and showed a small but significant reduction in nasal polyp size (0.5 on an 8-point scale) in patients with nasal polyps, suggesting a potential role for doxycycline in patients with polyps 2, 4

Macrolides carry important risks, including cardiac risks such as QT interval prolongation, gastrointestinal risks like diarrhea and abdominal cramps, and allergic and otologic risks, which must be weighed against potential benefits 1, 2

Confirm chronic rhinosinusitis (>12 weeks of symptoms) and examine for purulent drainage before considering antibiotics, emphasizing the importance of a thorough initial evaluation 1
Optimize anti-inflammatory treatment, including intranasal corticosteroids and saline nasal irrigations, before considering antibiotics, as these are the foundation of chronic rhinosinusitis management 1
Consider macrolides, such as roxithromycin or azithromycin, for 12 weeks if there is persistent purulent drainage after optimizing anti-inflammatory treatment, and prefer roxithromycin in patients without polyps and with low IgE 1
Consider doxycycline in patients with nasal polyps, given its potential benefits in reducing polyp size and postnasal drip 2, 4

Do not prescribe antibiotics empirically without evidence of active bacterial infection (purulent drainage), as this can contribute to antibiotic resistance and unnecessary side effects 1
Do not use short-course antibiotics (2-4 weeks) in stable chronic rhinosinusitis, as the evidence does not show benefit, and instead consider prolonged antibiotic treatment in specific cases 2, 3
Do not use macrolides as first-line treatment without first optimizing anti-inflammatory treatment, given the potential risks and side effects associated with macrolides 1
Do not ignore the cardiovascular risks of macrolides, especially in patients with cardiovascular risk factors, and carefully weigh the benefits and risks of antibiotic treatment in each patient 1